Psychedelic research and access in
Delaware
Delaware remains a baseline controlled-substances jurisdiction in this review. Delaware’s Uniform Controlled Substances Act schedules psilocybin, “psilocin” — the statute’s spelling — LSD, DMT, ibogaine and mescaline among hallucinogenic Schedule I substances, while also describing lawful administration or research in the presence of a practitioner or as a research subject under authorised conditions.
Key Insights
- 1
Delaware’s official code still treats psilocybin, “psilocin”, LSD, DMT, ibogaine and mescaline as Schedule I hallucinogens.
- 2
The strongest verified access signal is conventional care: Delaware Medicaid’s 2026 PDL includes SPRAVATO.
- 3
No verified Delaware psilocybin-services framework or public pilot was identified in the primary materials reviewed for this update.
- 4
Delaware should not be characterised as a psychedelic policy or research hub without additional primary-source verification.
Research Snapshot
Deep reportBlossom currently tracks 1 psychedelic clinical trial with verified sites in Delaware, including 1 active study.
- Active trials
- 1
- Total trials
- 1
- Stakeholders
- 2
- Events
- 0
Verified state-linked study sites
Linked trial records
2 physical, 0 jurisdiction-linked
Linked state-level events
Top Compounds
- Ketamine(1)
Top Study Topics
No study-topic signal is available from linked state trials yet.
Access and Reimbursement
Ketamine/esketamine access; no state-regulated classical psychedelic pathwayRealistically, Delaware patients can access ordinary ketamine care and FDA-approved esketamine, not a Delaware-specific classic-psychedelic services pathway. Delaware’s 2026 Medicaid Preferred Drug List includes SPRAVATO, which is a useful verified signal that plan-level esketamine access exists within the state’s Medicaid formulary structure. Esketamine nonetheless remains subject to the federal REMS, and off-label ketamine remains a separate clinical route.
Research signal
AvailableThe official sources reviewed for this update did not verify a distinctive Delaware psychedelic trial hub or state-backed pilot programme. gov, university or hospital source.
Ketamine / esketamine
AvailableRealistically, Delaware patients can access ordinary ketamine care and FDA-approved esketamine, not a Delaware-specific classic-psychedelic services pathway. Delaware’s 2026 Medicaid Preferred Drug List includes SPRAVATO, which is a useful verified signal that plan-level esketamine access exists within the state’s Medicaid formulary structure.
No state service model
Not AvailableNo state-regulated psilocybin, MDMA or natural-medicine service model is verified for Delaware.
Classical psychedelics
Not AvailableThe strongest verified policy fact is simply that Delaware continues to rely on its standard controlled-substance framework, which plainly continues to schedule classic psychedelics and accommodates lawful research through existing authorised routes. That is materially different from states that have adopted deprioritisation, decriminalisation or service-centre licensing.
Reimbursement / payment
LimitedDelaware has state-specific Medicaid or payer material relevant to esketamine, but current plan criteria should be rechecked before publication.
Policy and Access Timeline
State-level bills, laws, pilots, agency actions and reimbursement signals that shape real-world access.
1 Jan 2026
ActivePayer PolicyDelaware Medicaid’s preferred drug list included SPRAVATO as a formulary item
Delaware Medicaid’s preferred drug list included SPRAVATO as a formulary item.
DelawareDelaware Medicaid Preferred Drug List→1 Jan 1972
ActiveAgency GuidanceDelaware session laws codified the Uniform Controlled Substances Act structure that sch...
Delaware session laws codified the Uniform Controlled Substances Act structure that schedules classic psychedelics and sets authorised research/administration rules.
DelawareDelaware General Assembly Session Laws Chapter 424→
Regulatory Status
Delaware remains a baseline controlled-substances jurisdiction in this review. Delaware’s Uniform Controlled Substances Act schedules psilocybin, “psilocin” — the statute’s spelling — LSD, DMT, ibogaine and mescaline among hallucinogenic Schedule I substances, while also describing lawful administration or research in the presence of a practitioner or as a research subject under authorised conditions. On the official materials reviewed here, Delaware does not present a verified psilocybin-services framework, pilot law or local deprioritisation regime comparable to Colorado, Connecticut or DC. For publication purposes, Delaware should therefore be treated as having no verified state psychedelic-access pathway beyond ordinary research permissions and standard medical routes.
Medical Access Summary
Realistically, Delaware patients can access ordinary ketamine care and FDA-approved esketamine, not a Delaware-specific classic-psychedelic services pathway. Delaware’s 2026 Medicaid Preferred Drug List includes SPRAVATO, which is a useful verified signal that plan-level esketamine access exists within the state’s Medicaid formulary structure. Esketamine nonetheless remains subject to the federal REMS, and off-label ketamine remains a separate clinical route.###
No verified Delaware state programme for psilocybin, MDMA, ibogaine or DMT access was identified in the primary sources used for this update. Delaware pages should therefore stay conservative and avoid implying a special-access, state-pilot or regulated-services route unless an additional primary source is confirmed before publication.###
Local Research Map
Verified Blossom records with coordinates in Delaware, including trial sites, physical stakeholders and events.
Policy and Access Context
The strongest verified policy fact is simply that Delaware continues to rely on its standard controlled-substance framework, which plainly continues to schedule classic psychedelics and accommodates lawful research through existing authorised routes. That is materially different from states that have adopted deprioritisation, decriminalisation or service-centre licensing.###
For access analysis, that means Delaware is presently best described as a jurisdiction where classic psychedelic access is still effectively limited to federally compliant research contexts, while ordinary ketamine/esketamine care sits in the conventional healthcare system.###
Research Focus
The official sources reviewed for this update did not verify a distinctive Delaware psychedelic trial hub or state-backed pilot programme. That absence should shape editorial tone: Delaware should not be presented as a research hotspot without a directly verified ClinicalTrials.gov, university or hospital source.###
The safer framing is that Delaware remains research-possible in principle under ordinary law, but without a clearly verified local concentration of psychedelic clinical research in the materials used here.###
Implementation Context
No psychedelic-specific Delaware implementation machinery was verified in the primary materials used here. There is no verified Delaware facilitator licensing system, healing-centre regulator, advisory board or service-centre rule set in the sources reviewed for this page. The practical implementation backdrop is therefore ordinary controlled-substance oversight plus any case-specific lawful research approval pathways.###
For professional readers, that matters because Delaware should be read as a low-complexity, low-visibility jurisdiction: fewer moving regulatory parts, but also no verified special-access infrastructure.###
Ecosystem Context
Delaware’s verified ecosystem signals in this review are thin. The clearest grounded facts are the baseline legal position in the state code and Medicaid formulary visibility for SPRAVATO. Publication should therefore resist naming an in-state psychedelic ecosystem unless a local institution, clinic or organisation can be verified directly.###
That makes Delaware potentially useful as a comparator state: it shows what a market looks like when esketamine is visible in conventional pharmacotherapy channels but no comparable classic-psychedelic state framework has been verified.###
Key Milestones
Future Outlook
Over the next 12 to 24 months, Delaware’s likely near-term developments are more likely to come through ordinary medical channels, formulary decisions and external clinical research than through a home-grown psychedelic-services statute, at least based on the primary-source picture reviewed here.###
The main uncertainty is informational rather than interpretive: Delaware should be manually re-checked for any 2025-26 or 2026-27 legislative activity, trial-site activity or institutional programmes that were not visible in the materials captured for this draft.###
Sources and Verification
Last updated 15 May 2026. Source links are drawn from citation annotations in the subnational report.
State-Linked Stakeholders
Organisations with verified physical locations or jurisdiction-level coverage in Delaware.
Clinical Trials
Trial records with verified sites in Delaware.